Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis

Fig. 3

Promoter hyper-methylation contributes to downregulation of CLDN7. (A) MSP analysis of CLDN7 promoter DNA methylation status and RT-PCR analysis of CLDN7 mRNA expression in RCC cell lines. (B) Treatment with 5-aza-dC and TSA demethylated CLDN7 promoter and increased CLDN7 mRNA expression in Caki-1 and A498 cells. (C) The representative MSP analysis of CLDN7 promoter DNA methylation status in ccRCC tissues. (D) Representative results of bisulfite genomic sequencing analysis of DNA methylation status of CLDN7 promoter in two ccRCC patients (a. No.83 and b. No.85). DNA methylation status of the CLDN7 promoter in blue (normal) or red (tumor) filled circles indicate DNA methylation, open circles indicate absence of DNA methylation. Representative bisulfite genomic sequencing results of normal kidney tissues (c) and ccRCC tissues (d) in No.83 ccRCC patient. * indicate the CpG islands. T refers to Tumor tissue of ccRCC, N refers to Normal kidney tissue. U = Unmethylated, M = methylated. 5-Aza refers to 5-Aza-2′-deoxycytidine. T refes to Trichostatin A

Back to article page